Series A venture capital and seed funding rounds for biopharma firms in 2016 kept pace with the level of investment seen in 2015, excluding one major deal in 2015, laying the foundation for optimism regarding early-stage financings in 2017 for particularly innovative companies.
Money flowed to startups around the world in 2016 at a pace similar to 2015, providing for a steady stream of new companies to fill an important part of the biopharma ecosystem, and global venture capital is expected to keep pouring into drug discovery and development in 2017 as well.
Data gathered by Scrip and Informa Pharma Intelligence’s Strategic Transactions database show that 148 Series A and seed rounds totaling...
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
